Effect of Chronic Urocortin2 treatment following experimental myocardial infarction

Status: Complete
Year: 2007
Funded: $74,478
Grant Type: Major Project Grant

Clinical heart failure is often the result of myocardial infarction (MI) and the subsequent adaptive and maladaptive responses to MI. Within the heart, remodelling of the left ventricle and development of hypertrophy after infarction profoundly affects heart function, has been shown to be predictive of late heart failure and mortality. To date, successful treatment of heart failure has focussed on the manipulation of hormone systems that are activated in response to cardiac injury or dysfunction [1], via drugs such as ACE inhibitors or b-blockers. Despite advances in therapy, however, the overall outcome in heart failure remains very poor, and with an increasing incidence and prevalence, there is an indisputable need to explore new ways to treat this disease.

Researcher // Dr Leigh Ellmers – University of Otago

Dr Ellmers joined the Cardioendocrine Research Group as a Summer Student, and stayed on to do research towards a PhD. Her PhD the topic was Molecular studies of natriuretic peptides in cardiac fibrosis and hypertrophy. She graduated in 2001 with a PhD undertaken in the Department of Medicine, University of Otago.

More About Dr Leigh Ellmers

Stay in touch with CMRF

// Get all the latest news and insights to your inbox